Related Experiment Video
Updated: May 26, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
[Hemiplegic migraine: from historical perspectives to current management]
Mamoru Shibata1,2, Kazumasa Saigoh3, Daisuke Danno4
1Department of Neurology, Tokyo Dental College Ichikawa General Hospital.
Hemiplegic migraine, a rare condition causing temporary paralysis, is linked to specific gene mutations. Emerging research suggests calcitonin gene-related peptide (CGRP) therapies may offer new treatment options.
Area of Science:
- Neurology
- Genetics
Background:
- Hemiplegic migraine is a rare migraine subtype featuring reversible hemiplegia/hemiparesis as an aura.
- This condition significantly impairs quality of life due to prolonged motor symptoms.
Purpose of the Study:
- To review the genetic basis and therapeutic landscape of hemiplegic migraine.
- To highlight recent advancements in treatment strategies.
Main Methods:
- Literature review of hemiplegic migraine genetics and treatment.
- Analysis of current therapeutic options and contraindications.
- Evaluation of emerging therapies targeting CGRP.
Main Results:
- Familial hemiplegic migraine is associated with mutations in CACNA1A, ATP1A2, SCN1A, and PRRT2 genes.
- These mutations may lead to neuronal hyperexcitability and increased susceptibility to cortical spreading depression.
- Triptans are contraindicated for acute treatment, and preventive therapies are not well-established.
Conclusions:
- Current therapeutic options for hemiplegic migraine are limited.
- Calcitonin gene-related peptide-targeting monoclonal antibodies show promise as a potential treatment.
Related Concept Videos
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Ischemic Stroke l: Introduction
Stroke: Introduction and Types
Rheumatic Heart Disease III: Medical Management
Increased Intracranial Pressure l: Introduction
